Biocon Biologics to make new antibody to fight, prevent COVID

Biocon Biologics to make new antibody to fight, prevent COVID

by admin- Tuesday, July 27th, 2021 03:37:58 PM

Biocon Biologics a subsidiary of Biocon introduced that US based Adagio Therapeutics has granted an exclusive license to Biocon Biologics to manufacture and commercialize an antibody treatment primarily based on ADG20 for India and choose emerging markets.

ADG20, a novel monoclonal antibody focused on the spike protein of SARS-CoV-2 and related coronaviruses, is in global scientific development through Adagio as a unmarried agent for each the remedy and prevention of COVID-19, the disorder resulting from the SARS-CoV-2 virus, its variants, as well as future editions which can emerge.

News Updates